Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?

Zandelisib Shows Unexpectedly Positive Data

 
• By Alaric DeArment
  
Snails on the athletic track moves the finish line (By Sergey Lavrentev. Shutterstock 463225937)
MEI/Kyowa Kirin's zandelisib appears to pull ahead of other PI3K-delta inhibitors on efficacy and safety • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category